Global Intermediate CDMO Market Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06262254

Publication Date:

June 16, 2025

Pages:

135

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Intermediate CDMO market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Intermediate CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Intermediate CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Intermediate CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Intermediate CDMO players cover Pharmira, AGC Inc, Blue Jet Healthcare, Drug Discovery Alliances, KriSan Biotech, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淚ntermediate CDMO Industry Forecast鈥� looks at past sales and reviews total world Intermediate CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Intermediate CDMO sales for 2025 through 2031. With Intermediate CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intermediate CDMO industry.
This Insight Report provides a comprehensive analysis of the global Intermediate CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Intermediate CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Intermediate CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intermediate CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intermediate CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Intermediate CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antibiotic Intermediates
Antipyretic and Analgesic Intermediate
Cardiovascular System Drug Intermediates
Anticancer Drug Intermediates
Segmentation by Application:
Pharmaceutical Company
Biotechnology Company
Generic Company
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pharmira
AGC Inc
Blue Jet Healthcare
Drug Discovery Alliances
KriSan Biotech
Saurav Chemicals
Olon SpA
AGC Biologics
Fermion
Pfizer CentreOne
Aspen Holdings
Educell
Hovione
Porton Pharma Solutions
Sinopep
Chongqing Huapont Pharmaceutical
Langhua Pharmaceutical

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Intermediate CDMO Market Size (2020-2031)
2.1.2 Intermediate CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Intermediate CDMO by Country/Region (2020, 2024 & 2031)
2.2 Intermediate CDMO Segment by Type
2.2.1 Antibiotic Intermediates
2.2.2 Antipyretic and Analgesic Intermediate
2.2.3 Cardiovascular System Drug Intermediates
2.2.4 Anticancer Drug Intermediates
2.3 Intermediate CDMO Market Size by Type
2.3.1 Intermediate CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Intermediate CDMO Market Size Market Share by Type (2020-2025)
2.4 Intermediate CDMO Segment by Application
2.4.1 Pharmaceutical Company
2.4.2 Biotechnology Company
2.4.3 Generic Company
2.4.4 Others
2.5 Intermediate CDMO Market Size by Application
2.5.1 Intermediate CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Intermediate CDMO Market Size Market Share by Application (2020-2025)
3 Intermediate CDMO Market Size by Player
3.1 Intermediate CDMO Market Size Market Share by Player
3.1.1 Global Intermediate CDMO Revenue by Player (2020-2025)
3.1.2 Global Intermediate CDMO Revenue Market Share by Player (2020-2025)
3.2 Global Intermediate CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Intermediate CDMO by Region
4.1 Intermediate CDMO Market Size by Region (2020-2025)
4.2 Global Intermediate CDMO Annual Revenue by Country/Region (2020-2025)
4.3 Americas Intermediate CDMO Market Size Growth (2020-2025)
4.4 APAC Intermediate CDMO Market Size Growth (2020-2025)
4.5 Europe Intermediate CDMO Market Size Growth (2020-2025)
4.6 Middle East & Africa Intermediate CDMO Market Size Growth (2020-2025)
5 Americas
5.1 Americas Intermediate CDMO Market Size by Country (2020-2025)
5.2 Americas Intermediate CDMO Market Size by Type (2020-2025)
5.3 Americas Intermediate CDMO Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Intermediate CDMO Market Size by Region (2020-2025)
6.2 APAC Intermediate CDMO Market Size by Type (2020-2025)
6.3 APAC Intermediate CDMO Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Intermediate CDMO Market Size by Country (2020-2025)
7.2 Europe Intermediate CDMO Market Size by Type (2020-2025)
7.3 Europe Intermediate CDMO Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Intermediate CDMO by Region (2020-2025)
8.2 Middle East & Africa Intermediate CDMO Market Size by Type (2020-2025)
8.3 Middle East & Africa Intermediate CDMO Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Intermediate CDMO Market Forecast
10.1 Global Intermediate CDMO Forecast by Region (2026-2031)
10.1.1 Global Intermediate CDMO Forecast by Region (2026-2031)
10.1.2 Americas Intermediate CDMO Forecast
10.1.3 APAC Intermediate CDMO Forecast
10.1.4 Europe Intermediate CDMO Forecast
10.1.5 Middle East & Africa Intermediate CDMO Forecast
10.2 Americas Intermediate CDMO Forecast by Country (2026-2031)
10.2.1 United States Market Intermediate CDMO Forecast
10.2.2 Canada Market Intermediate CDMO Forecast
10.2.3 Mexico Market Intermediate CDMO Forecast
10.2.4 Brazil Market Intermediate CDMO Forecast
10.3 APAC Intermediate CDMO Forecast by Region (2026-2031)
10.3.1 China Intermediate CDMO Market Forecast
10.3.2 Japan Market Intermediate CDMO Forecast
10.3.3 Korea Market Intermediate CDMO Forecast
10.3.4 Southeast Asia Market Intermediate CDMO Forecast
10.3.5 India Market Intermediate CDMO Forecast
10.3.6 Australia Market Intermediate CDMO Forecast
10.4 Europe Intermediate CDMO Forecast by Country (2026-2031)
10.4.1 Germany Market Intermediate CDMO Forecast
10.4.2 France Market Intermediate CDMO Forecast
10.4.3 UK Market Intermediate CDMO Forecast
10.4.4 Italy Market Intermediate CDMO Forecast
10.4.5 Russia Market Intermediate CDMO Forecast
10.5 Middle East & Africa Intermediate CDMO Forecast by Region (2026-2031)
10.5.1 Egypt Market Intermediate CDMO Forecast
10.5.2 South Africa Market Intermediate CDMO Forecast
10.5.3 Israel Market Intermediate CDMO Forecast
10.5.4 Turkey Market Intermediate CDMO Forecast
10.6 Global Intermediate CDMO Forecast by Type (2026-2031)
10.7 Global Intermediate CDMO Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Intermediate CDMO Forecast
11 Key Players Analysis
11.1 Pharmira
11.1.1 Pharmira Company Information
11.1.2 Pharmira Intermediate CDMO Product Offered
11.1.3 Pharmira Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Pharmira Main Business Overview
11.1.5 Pharmira Latest Developments
11.2 AGC Inc
11.2.1 AGC Inc Company Information
11.2.2 AGC Inc Intermediate CDMO Product Offered
11.2.3 AGC Inc Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 AGC Inc Main Business Overview
11.2.5 AGC Inc Latest Developments
11.3 Blue Jet Healthcare
11.3.1 Blue Jet Healthcare Company Information
11.3.2 Blue Jet Healthcare Intermediate CDMO Product Offered
11.3.3 Blue Jet Healthcare Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Blue Jet Healthcare Main Business Overview
11.3.5 Blue Jet Healthcare Latest Developments
11.4 Drug Discovery Alliances
11.4.1 Drug Discovery Alliances Company Information
11.4.2 Drug Discovery Alliances Intermediate CDMO Product Offered
11.4.3 Drug Discovery Alliances Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Drug Discovery Alliances Main Business Overview
11.4.5 Drug Discovery Alliances Latest Developments
11.5 KriSan Biotech
11.5.1 KriSan Biotech Company Information
11.5.2 KriSan Biotech Intermediate CDMO Product Offered
11.5.3 KriSan Biotech Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 KriSan Biotech Main Business Overview
11.5.5 KriSan Biotech Latest Developments
11.6 Saurav Chemicals
11.6.1 Saurav Chemicals Company Information
11.6.2 Saurav Chemicals Intermediate CDMO Product Offered
11.6.3 Saurav Chemicals Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Saurav Chemicals Main Business Overview
11.6.5 Saurav Chemicals Latest Developments
11.7 Olon SpA
11.7.1 Olon SpA Company Information
11.7.2 Olon SpA Intermediate CDMO Product Offered
11.7.3 Olon SpA Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Olon SpA Main Business Overview
11.7.5 Olon SpA Latest Developments
11.8 AGC Biologics
11.8.1 AGC Biologics Company Information
11.8.2 AGC Biologics Intermediate CDMO Product Offered
11.8.3 AGC Biologics Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 AGC Biologics Main Business Overview
11.8.5 AGC Biologics Latest Developments
11.9 Fermion
11.9.1 Fermion Company Information
11.9.2 Fermion Intermediate CDMO Product Offered
11.9.3 Fermion Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Fermion Main Business Overview
11.9.5 Fermion Latest Developments
11.10 Pfizer CentreOne
11.10.1 Pfizer CentreOne Company Information
11.10.2 Pfizer CentreOne Intermediate CDMO Product Offered
11.10.3 Pfizer CentreOne Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Pfizer CentreOne Main Business Overview
11.10.5 Pfizer CentreOne Latest Developments
11.11 Aspen Holdings
11.11.1 Aspen Holdings Company Information
11.11.2 Aspen Holdings Intermediate CDMO Product Offered
11.11.3 Aspen Holdings Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Aspen Holdings Main Business Overview
11.11.5 Aspen Holdings Latest Developments
11.12 Educell
11.12.1 Educell Company Information
11.12.2 Educell Intermediate CDMO Product Offered
11.12.3 Educell Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Educell Main Business Overview
11.12.5 Educell Latest Developments
11.13 Hovione
11.13.1 Hovione Company Information
11.13.2 Hovione Intermediate CDMO Product Offered
11.13.3 Hovione Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Hovione Main Business Overview
11.13.5 Hovione Latest Developments
11.14 Porton Pharma Solutions
11.14.1 Porton Pharma Solutions Company Information
11.14.2 Porton Pharma Solutions Intermediate CDMO Product Offered
11.14.3 Porton Pharma Solutions Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Porton Pharma Solutions Main Business Overview
11.14.5 Porton Pharma Solutions Latest Developments
11.15 Sinopep
11.15.1 Sinopep Company Information
11.15.2 Sinopep Intermediate CDMO Product Offered
11.15.3 Sinopep Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Sinopep Main Business Overview
11.15.5 Sinopep Latest Developments
11.16 Chongqing Huapont Pharmaceutical
11.16.1 Chongqing Huapont Pharmaceutical Company Information
11.16.2 Chongqing Huapont Pharmaceutical Intermediate CDMO Product Offered
11.16.3 Chongqing Huapont Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Chongqing Huapont Pharmaceutical Main Business Overview
11.16.5 Chongqing Huapont Pharmaceutical Latest Developments
11.17 Langhua Pharmaceutical
11.17.1 Langhua Pharmaceutical Company Information
11.17.2 Langhua Pharmaceutical Intermediate CDMO Product Offered
11.17.3 Langhua Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 Langhua Pharmaceutical Main Business Overview
11.17.5 Langhua Pharmaceutical Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂